

GI Expanded Bacterial Assay (Panther Fusion™ System)

For *in vitro* diagnostic use only

For U.S. Export Only

TABLE OF CONTENTS

| | |
|---|-----------|
| General Information | 2 |
| Intended Use | 2 |
| Summary and Explanation of the Test | 2 |
| Principles of the Procedure | 3 |
| Warnings and Precautions | 4 |
| Reagent Storage and Handling Requirements | 7 |
| Specimen Collection and Storage | 8 |
| Specimen Transport | 9 |
| Panther Fusion System | 10 |
| Reagents and Materials Provided for Panther Fusion GI Expanded Bacterial Assay | 10 |
| Materials Required and Available Separately | 11 |
| Panther Fusion System Test Procedure | 12 |
| Procedural Notes | 13 |
| Quality Control | 14 |
| Negative and Positive Controls | 14 |
| Internal Control | 14 |
| Interpretation of Results | 15 |
| Limitations | 16 |
| Analytical Performance | 17 |
| Analytical Sensitivity | 17 |
| Inclusivity/Reactivity - Wet Testing | 17 |
| Inclusivity/Reactivity - In Silico Analysis | 20 |
| Analytical Specificity: Cross-Reactivity and Microbial Interference - Wet Testing . . . | 20 |
| Coinfection/Competitive Interference | 22 |
| Interference | 23 |
| Carryover Contamination | 26 |
| Within Laboratory Precision/Repeatability | 26 |
| Reproducibility | 27 |
| Clinical Performance | 29 |
| Bibliography | 32 |
| Contact Information | 33 |

General Information

Intended Use

The Panther Fusion™ GI Expanded Bacterial Assay is a multiplex real-time PCR *in vitro* diagnostic test for the rapid and qualitative detection and differentiation of *Yersinia enterocolitica*, *Vibrio* (*V. parahaemolyticus*, *V. vulnificus*, *V. cholerae*), *Escherichia coli* O157, and *Plesiomonas shigelloides*. Nucleic acids are isolated and purified from preserved stool specimens collected from individuals exhibiting signs and symptoms of gastroenteritis.

This assay is intended to aid in the differential diagnosis of *Yersinia enterocolitica*, *Vibrio* (*V. parahaemolyticus*, *V. vulnificus*, *V. cholerae*), *Escherichia coli* O157, and *Plesiomonas shigelloides* infections. The results of this assay should be used in conjunction with clinical presentation, laboratory findings, and epidemiological information and should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Positive results do not rule out coinfection with other organisms that are not detected by this test and may not be the sole or definitive cause of patient illness. Negative results in the setting of clinical illness compatible with gastroenteritis may be due to infection by pathogens that are not detected by this test, or non-infectious causes such as ulcerative colitis, irritable bowel syndrome, or Crohn's disease. This assay is designed for use on the Panther Fusion™ System.

Summary and Explanation of the Test

Acute diarrhea is a leading cause of outpatient visits, hospitalization, and lost quality of life in both domestic settings and among those traveling abroad. The global impact of foodborne disease is substantial with an estimated 600 million people becoming ill, resulting in 420,000 deaths annually.¹ The Centers for Disease Control and Prevention (CDC) has estimated 48 million cases of foodborne illness annually in the US leading to 128,000 hospitalizations and 3,000 deaths.² Acute diarrhea is associated with estimated healthcare costs upwards of \$150 million.³

Infectious gastroenteritis can be caused by a variety of bacterial, viral, and parasitic organisms. Symptoms alone cannot be used to distinguish the cause of the infection, making rapid and accurate diagnostic tools essential for guiding treatment and patient management.

CDC estimates *Y. enterocolitica* causes 116,716 illnesses, 637 hospitalizations, and 34 deaths in the United States every year.⁴ Children are infected more often than adults, and the infection is more common in the winter.⁵

Vibriosis causes an estimated 80,000 illnesses and 100 deaths in the United States every year. Most infections occur from May through October when water temperatures are warmer.⁶ About 52,000 of these illnesses are estimated to be the result of eating contaminated food.⁶ The most commonly reported species, *V. parahaemolyticus*, is estimated to cause 45,000 illnesses each year in the United States.⁵

An estimated 265,000 Shigatoxin *Escherichia coli* (STEC) infections occur each year in the United States, with STEC O157 causing about 36% of these infections.⁴ Public health experts rely on estimates rather than actual numbers of infections because not all STEC infections are diagnosed.⁷

Outbreaks of diarrheal disease have been associated with contaminated water and oysters containing *P. shigelloides*, and reduction in the severity and duration of symptoms following appropriate antimicrobial therapy has been observed.⁸

Principles of the Procedure

The Panther Fusion System fully automates specimen processing, including sample lysis, nucleic acid capture, amplification, and detection for the Panther Fusion GI Expanded Bacterial Assay. Nucleic acid capture and elution take place in a single tube on the Panther Fusion System. The eluate is transferred to the Panther Fusion System reaction tube containing the assay reagents. Multiplex real-time PCR is then performed for the eluted nucleic acid on the Panther Fusion System.

Sample processing: Prior to processing and testing on the Panther Fusion System, specimens are transferred to an Aptima™ Multitest tube containing specimen transport media (STM) that lyses the cells, releases target nucleic acid, and protects them from degradation during storage.

Nucleic acid capture and elution: An internal control (IC-B) is added automatically to each specimen via the working Panther Fusion Capture Reagent-B (wFCR-B) to monitor for interference during specimen processing, amplification, and detection caused by reagent failure or inhibitory substances. Specimens are first incubated in an alkaline reagent (FER-B) to enable cell lysis. Nucleic acid released during the lysis step hybridizes to magnetic particles in the wFCR-B. The capture particles are then separated from residual specimen matrix in a magnetic field by a series of wash steps with a mild detergent. The captured nucleic acid is then eluted from the magnetic particles with a reagent of low ionic strength (Panther Fusion Elution Buffer).

Note: The Panther Fusion System adds the IC-B to the Panther Fusion Capture Reagent-B (FCR-B). After the IC-B is added to the FCR-B, it is referred to as wFCR-B (working FCR-B).

Multiplex PCR amplification and fluorescence detection: Lyophilized single unit dose reaction master mix is reconstituted with the Panther Fusion Reconstitution Buffer I and then combined with the eluted nucleic acid into a reaction tube. Panther Fusion Oil reagent is added to prevent evaporation during the PCR reaction.

Target-specific primers and probes then amplify targets via polymerase chain reaction while simultaneously measuring fluorescence of the multiplexed targets. The Panther Fusion System compares the fluorescence signal to a predetermined cutoff to produce a qualitative result for the presence or absence of each analyte.

The analytes and the channel used for their detection on the Panther Fusion System are summarized in the table below:

| Analyte | Gene Targeted | Instrument Channel |
|---------------------------------|---|--------------------|
| <i>Yersinia enterocolitica</i> | <i>InvA</i> (Invasive antigen A) | FAM |
| <i>Vibrio parahaemolyticus</i> | <i>gyrB</i> (Gyrase B) | HEX |
| <i>Vibrio vulnificus</i> | <i>gyrB</i> (Gyrase B) | HEX |
| <i>Vibrio cholerae</i> | <i>ompW</i> (Outer Membrane Protein W) | HEX |
| <i>Escherichia coli</i> O157 | <i>rfbE</i> (Perosamine synthase-O-antigen) | ROX |
| <i>Plesiomonas shigelloides</i> | <i>hugA</i> (Heme utilization gene A) | RED647 |
| Internal Control | Not Applicable | RED677 |

Warnings and Precautions

- A. For *in vitro* diagnostic use.
- B. Carefully read this entire package insert and the *Panther™/Panther Fusion System Operator's Manual*.
- C. The Panther Fusion Enhancer Reagent-B (FER-B) is corrosive, harmful if swallowed, and causes severe skin burns and eye damage.
- D. Only personnel adequately trained on the use of this assay and in handling potentially infectious materials should perform these procedures. If a spill occurs, immediately disinfect using appropriate site procedures.

Laboratory Related

- E. Use only supplied or specified disposable laboratory ware.
- F. Wear disposable, powderless gloves, protective eye wear, and laboratory coats when handling specimens and reagents. Wash hands thoroughly after handling specimens and reagents.
- G. Dispose of all material that has come into contact with specimens and reagents in accordance with applicable national, international, and regional regulations.

Specimen Related

- H. Handle all specimens as if infectious, using safe laboratory procedures such as those outlined in CDC/NIH Biosafety in Microbiological and Biomedical Laboratories and in the CLSI Document M29 Protection of Laboratory Workers from Occupationally Acquired Infections.⁹
- I. Expiration dates listed on the Aptima Multitest tubes pertain to the transfer of sample into the tube and not to testing of the sample. Specimens collected/transferred any time prior to these expiration dates are valid for testing provided they are transported and stored in accordance with the appropriate package insert, even if these expiration dates have passed.
- J. Maintain proper storage conditions during specimen shipping to ensure the integrity of the specimen. Specimen stability under shipping conditions other than those recommended has not been evaluated.
- K. Avoid cross-contamination during the specimen handling steps. Specimens can contain extremely high levels of bacteria or other organisms. Ensure that specimen containers do not come in contact with one another, and discard used materials without passing them over any open containers. Change gloves if they come in contact with specimens.

Assay Related

- L. Do not use the reagents and controls after the expiration date.
- M. Store assay components at the recommended storage condition. See *Reagent Storage and Handling Requirements* and *Panther Fusion System Test Procedure* for more information.
- N. Do not combine any assay reagents or fluids. Do not top off reagents or fluids; the Panther Fusion System verifies reagent levels.
- O. Avoid microbial and nuclease contamination of reagents.
- P. Quality control requirements must be performed in conformance with local, state, and/or federal regulations or accreditation requirements and your laboratory's standard quality control procedures.
- Q. Do not use the assay cartridge if the storage pouch is compromised or if the assay cartridge foil is not intact. Contact Hologic Technical Support if either occurs.
- R. Do not use the fluid packs if the foil seal is leaking. Contact Hologic Technical Support if this occurs.
- S. Handle the assay cartridges with care. Do not drop or invert assay cartridges. Avoid prolonged exposure to ambient light.
- T. Some reagents of this kit are labeled with hazard information.

Note: For more information on any hazard and precautionary statements that may be associated with reagents refer to the Safety Data Sheet Library at www.hologicsds.com. For more information on the symbols, refer to the symbol legend on <http://www.hologic.com/package-inserts>.

Canada Hazard Information**Panther Fusion Enhancer Reagent-B (FER-B)**

Lithium Hydroxide, Monohydrate 5 - 10%

**DANGER**

H302 - Harmful if swallowed

H314 - Causes severe skin burns and eye damage

P264 - Wash face, hands and any exposed skin thoroughly after handling

P270 - Do not eat, drink or smoke when using this product

P330 - Rinse mouth

P501 - Dispose of contents/container to an approved waste disposal plant

P260 - Do not breathe dusts or mists

P280 - Wear protective gloves/protective clothing/eye protection/face protection

P301 + P330 + P331 - IF SWALLOWED: Rinse mouth. Do NOT induce vomiting

P303 + P361 + P353 - IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water/shower

P304 + P340 - IF INHALED: Remove person to fresh air and keep comfortable for breathing

P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing

P321 - Specific treatment (see supplemental first aid instructions in the SDS)

P363 - Wash contaminated clothing before reuse

P405 - Store locked up

P301+ P317 - IF SWALLOWED: Get medical help

P316 - Get emergency medical help immediately

Reagent Storage and Handling Requirements

A. The following table provides storage and handling requirements for this assay.

| Reagent | Unopened Storage | On Board/ Open Stability ^a | Opened Storage |
|---|------------------|--|---------------------------|
| Panther Fusion GI Expanded Bacterial Assay Cartridge | 2°C to 8°C | 60 days | 2°C to 8°C ^b |
| Panther Fusion Capture Reagent-B (FCR-B) | 15°C to 30°C | 30 days | 15°C to 30°C |
| Panther Fusion Enhancer Reagent-B (FER-B) | 15°C to 30°C | 30 days | 15°C to 30°C |
| Panther Fusion Internal Control-B (IC-B) | 2°C to 8°C | (In wFCR-B) | Not applicable |
| Panther Fusion Elution Buffer | 15°C to 30°C | 60 days | 15°C to 30°C |
| Panther Fusion Oil | 15°C to 30°C | 60 days | 15°C to 30°C |
| Panther Fusion Reconstitution Buffer I | 15°C to 30°C | 60 days | 15°C to 30°C |
| Panther Fusion GI Expanded Bacterial Positive Control | 2°C to 8°C | Single use vial | Not applicable-single use |
| Panther Fusion Negative Control | 2°C to 8°C | Single use vial | Not applicable-single use |

When reagents are removed from the Panther Fusion System, return them immediately to their appropriate storage temperatures.

^a On-board stability starts at the time the reagent is placed on the Panther Fusion System for the Panther Fusion GI Expanded Bacterial Assay cartridge, FCR-B, FER-B, and IC-B. On-board stability for the Panther Fusion Reconstitution Buffer I, Panther Fusion Elution Buffer, and Panther Fusion Oil Reagent starts when the reagent pack is first used.

^b If removed from the Panther Fusion System, store the assay cartridge in an air-tight container with desiccant at the recommended storage temperature.

- B. Working Panther Fusion Capture Reagent-B (wFCR-B) and Panther Fusion Enhancer Reagent-B (FER-B) are stable for 60 days when capped and stored at 15°C to 30°C. Do not refrigerate.
- C. Controls are stable until the date indicated on the vials.
- D. Discard any unused reagents that have surpassed their on board stability.
- E. Avoid cross-contamination during reagent handling and storage.
- F. **Do not freeze reagents.**

Specimen Collection and Storage

Specimens – Clinical material collected from patient and placed in an appropriate transport system. For the Panther Fusion GI Expanded Bacterial Assay, this includes raw stool preserved in Cary-Blair transport media.

Samples – Represents a more generic term to describe any material for testing on the Panther Fusion System including specimens, specimens transferred into an Aptima Multitest tube and controls.

Note: Handle all specimens as if they contain potentially infectious agents. Use Universal Precautions.

Note: Take care to avoid cross-contamination during specimen handling steps. For example, discard used material without passing over open tubes.

A. Specimen types include stool samples preserved in Cary-Blair transport media.

Collect raw stool following appropriate standard stool collection and handling procedures. Transfer raw stool specimens into Cary-Blair transport media according to manufacturer's instructions.

B. Specimen Processing

1. Mix Cary-Blair preserved specimen thoroughly to ensure homogeneity immediately prior to transfer into the Aptima Multitest tube.

2. Prior to testing on the Panther Fusion System, transfer specimen to an Aptima Multitest tube.

a. Partially peel open the swab package. Remove the swab. Do not touch the soft tip or lay the swab down. If the soft tip is touched, the swab is laid down, or the swab is dropped, use a new Aptima™ Multitest Swab Specimen Collection Kit. Completely submerge the soft tip of the swab in Cary-Blair preserved stool specimen.

Note: Submerge only the soft tip of the swab 1 time in the liquid part, ensuring the pink shaft is not submerged.

b. Uncap the Aptima Multitest tube containing the transport medium. If the contents of the tube are spilled, use a new Aptima Multitest Swab Specimen Collection Kit. Place the swab in the tube and gently swirl the swab in the tube for 5 seconds to release material. Leave the swab in the tube.

c. Carefully break the swab shaft at the score line against the side of the tube and discard the top portion of the swab shaft.

d. Affix the provided or new penetrable cap to the tube.

3. Storing specimens before testing

a. After collection, the Cary-Blair preserved specimens can be stored at 2°C to 8°C for up to 72 hours before transfer to the Aptima Multitest tube.

Note: *Yersinia* is affected by storage temperature and time. If samples are not stored appropriately, they may have reduced recovery and lose their positive results.

b. Specimen in the Aptima Multitest tube may be stored under 1 of the following conditions:

- 15°C to 30°C for up to 6 days or
- 2°C to 8°C for up to 30 days or
- ≤ -20°C for up to 3 months

Note: Do not exceed 1 freeze-thaw cycle. Multiple freeze-thaw cycles may lead to sample degradation.

Note: It is recommended that specimens transferred to the Aptima Multitest tube are stored capped and upright in a rack.

C. Specimen Storage after Testing

1. Samples that have been assayed should be stored upright in the rack under 1 of the following conditions:

- 15°C to 30°C for up to 6 days or
- 2°C to 8°C for up to 30 days or
- ≤ -20°C for up to 3 months

Note: Do not exceed 1 freeze-thaw cycle. Multiple freeze-thaw cycles may lead to sample degradation.

2. The samples should be covered with a new, clean plastic film or foil barrier.
3. If assayed samples need to be frozen or shipped, remove the penetrable cap and place a new non-penetrable cap on the specimen tubes. If samples need to be shipped for testing at another facility, recommended temperatures must be maintained. Prior to uncapping, specimen transport tubes must be kept upright for 5 minutes to bring all of the liquid down to the bottom of the tube. Avoid splashing and cross-contamination. Do not centrifuge.

Specimen Transport

Maintain specimen storage conditions during transport as described under *Specimen Collection and Storage*.

Note: Specimens must be shipped in accordance with applicable national, international, and regional transportation regulations.

Panther Fusion System

The Panther Fusion System is an integrated nucleic acid testing system that fully automates all steps necessary to perform various Panther Fusion assays from sample processing through amplification, detection, and data reduction.

Reagents and Materials Provided for Panther Fusion GI Expanded Bacterial Assay

Assay Packaging

| Components | Part No. | Storage |
|---|-----------|--------------|
| Panther Fusion GI Expanded Bacterial Assay Cartridge 96 Tests Panther Fusion GI Expanded Bacterial Assay cartridge, 12 tests, 8 per box | PRD-07121 | 2°C to 8°C |
| Panther Fusion Internal Control-B 960 Tests Panther Fusion Internal Control-B tube, 4 per box | PRD-06234 | 2°C to 8°C |
| Panther Fusion GI Expanded Bacterial Assay Controls Panther Fusion GI Expanded Bacterial Positive Control tube, 5 per box Panther Fusion Negative Control tube, 5 per box | PRD-07122 | 2°C to 8°C |
| Panther Fusion Extraction Reagent-B 960 Tests Panther Fusion Capture Reagent-B bottle, 240 tests, 4 per box Panther Fusion Enhancer Reagent-B bottle, 240 tests, 4 per box | PRD-06232 | 15°C to 30°C |
| Panther Fusion Elution Buffer 2400 Tests Panther Fusion Elution Buffer pack, 1200 tests, 2 per box | PRD-04334 | 15°C to 30°C |
| Panther Fusion Reconstitution Buffer I 1920 Tests Panther Fusion Reconstitution Buffer I, 960 Tests, 2 per box | PRD-04333 | 15°C to 30°C |
| Panther Fusion Oil Reagent 1920 Tests Panther Fusion Oil Reagent, 960 tests, 2 per box | PRD-04335 | 15°C to 30°C |

Individually Packaged Items

| Items | Part No. |
|---|-----------|
| Panther Fusion Tube Trays, 1008 Tests, 18 trays per box | PRD-04000 |
| Aptima Multitest Specimen Collection Kit, pack of 50 | PRD-03546 |

Materials Required and Available Separately

Note: Materials available from Hologic have catalog numbers listed, unless otherwise specified.

| Material | Cat. No. |
|--|--|
| Panther System | 303095 |
| Panther Fusion System | PRD-04172 |
| Panther System Continuous Fluid and Waste (Panther Plus) | PRD-06067 |
| Aptima™ Assay Fluids Kit (Aptima Wash Solution, Aptima Buffer for Deactivation Fluid, and Aptima Oil Reagent) | 303014 (1000 tests) |
| Multi-tube units (MTUs) | 104772-02 |
| Panther Waste Bag Kit | 902731 |
| Panther Waste Bin Cover | 504405 |
| Or Panther System Run Kit contains MTUs, waste bags, waste bin covers, assay fluids, and auto detects ^a | 303096 (5000 tests) |
| Tips, 1000 µL, filtered, liquid-sensing, conductive, and disposable: | 901121 (10612513 Tecan) 903031 (10612513 Tecan) |
| Not all products are available in all regions. Contact your representative for region-specific information. | MME-04134 (30180117 Tecan) MME-04128 MME-04110 |
| Aptima penetrable caps (optional) | 105668 |
| Replacement non-penetrable caps (optional) | 103036A |
| Replacement extraction reagent bottle caps | CL0040 |
| Bleach, 5% to 8.25% (0.7 M to 1.16 M) sodium hypochlorite solution Note: Refer to the <i>Panther/Panther Fusion System Operator's Manual</i> for instructions on preparing diluted sodium hypochlorite solution. | — |
| Disposable powderless gloves | — |

^a Needed only for Aptima assays that use TMA technology.

Optional Materials

| Material | Cat. No. |
|--|----------|
| Benchtop Vortex (VWR Analog Vortex Mixer 120V, Cat. No. 10153-838) or equivalent | — |

Panther Fusion System Test Procedure

Note: Refer to the *Panther/Panther Fusion System Operator's Manual* for additional procedural information.

A. Work Area Preparation

1. Wipe down work surfaces with 2.5% to 3.5% (0.35 M to 0.5 M) sodium hypochlorite solution. Allow the sodium hypochlorite solution to contact surfaces for at least 1 minute and follow with a deionized (DI) water rinse. Do not allow the sodium hypochlorite solution to dry. Cover the bench surface with clean, plastic-backed absorbent laboratory bench covers.

B. Reagent Preparation

1. Remove the bottles of IC-B, FCR-B, and FER-B from storage.
2. Mix FCR-B by gently swirling until full resuspension of the beads. Avoid creating foam during this step.
3. Open the bottles of IC-B, FCR-B, and FER-B, and discard the caps. Open the TCR door on the upper bay of the Panther Fusion System.
4. Place the IC-B, FCR-B, and FER-B bottles in the appropriate positions on the TCR carousel.
5. Close the TCR door.

Note: The Panther Fusion System adds the IC-B to the FCR-B. After the IC-B is added to the FCR-B, it is referred to as wFCR-B (working FCR-B). If the wFCR-B and FER-B are removed from the system, use new caps and immediately store according to the proper storage conditions.

C. Specimen Handling

1. Visually confirm that each specimen tube contains a single pink Aptima collection swab in the Aptima Multitest tube. If the Aptima Multitest tube contains no swab, multiple swabs, or a swab not provided by Hologic, the transfer of stool in Cary-Blair media should be repeated using a new Aptima Multitest Swab Specimen Collection Kit.
2. Verify the appearance of the sample in the Aptima Multitest tube.
 - a. If the specimen is homogeneous, proceed with testing.
 - b. If solids or mucoidal materials are observed, note that these can interfere with the test.

Note: If any invalid flags are observed when processing specimens (e.g., CLT, icrfu, ebh or ebl), samples in the Aptima Multitest tube may be vortexed after replacing with a new penetrable cap for 30 to 60 seconds at maximum speed on a standard bench top vortex prior to retesting.

Note: Prepare specimens per the Specimen Processing instructions in the Specimen Collection and Storage section before loading specimens onto the Panther Fusion System.

D. System Preparation

For instructions on setting up the Panther Fusion System including loading samples, reagents, assay cartridges and universal fluids, refer to the *Panther/Panther Fusion System Operator's Manual*.

Procedural Notes

A. Controls

1. The Panther Fusion GI Expanded Bacterial Positive Control and the Panther Fusion Negative Control can be loaded in any rack position, in any Sample Bay lane on the Panther Fusion System.
2. Once the control tubes are pipetted and processed for the Panther Fusion GI Expanded Bacterial Assay, they are valid for up to 30 days (control frequency configured by an administrator) unless control results are invalid or a new assay cartridge lot is loaded.
3. Each control tube can be tested once.
4. Patient specimen pipetting begins when 1 of the following 2 conditions is met:
 - a. Valid results for the controls are registered on the system.
 - b. A pair of controls is currently in process on the system.

Quality Control

A run or specimen result may be invalidated by the Panther Fusion System if problems occur while performing the assay. Specimens with invalid results must be retested.

Negative and Positive Controls

To generate valid results, a set of assay controls must be tested. One (1) replicate of the negative assay control and positive assay control must be tested each time a new lot of assay cartridges is loaded on the Panther Fusion System or when the current set of valid controls for an active cartridge lot have expired.

The Panther Fusion System is configured to require assay controls run at an administrator-specified interval of up to 30 days. Software on the Panther Fusion System alerts the operator when assay controls are required and does not start new tests until the assay controls are loaded and have started processing.

During processing, criteria for acceptance of the assay controls are automatically verified by the Panther Fusion System. To generate valid results, the assay controls must pass a series of validity checks performed by the Panther Fusion System.

If the assay controls pass all validity checks, they are considered valid for the administrator-specified time interval. When the time interval has passed, the assay controls are expired by the Panther Fusion System and a new set of assay controls will be required prior to starting any new samples.

If any one of the assay controls fails the validity checks, the Panther Fusion System automatically invalidates the affected samples and a new set of assay controls will be required prior to testing any new samples.

Internal Control

An internal control is added to each sample during the extraction process. During processing, the internal control acceptance criteria is automatically verified by the Panther Fusion System software. Detection of the internal control is not required for samples that are positive for *Yersinia enterocolitica*, *Vibrio* species, *Escherichia coli* O157, and/or *Plesiomonas shigelloides*. The internal control must be detected in all samples that are negative for all of the intended analytes; samples that fail to meet that criteria will be reported as Invalid. Each sample with an Invalid result must be retested.

The Panther Fusion System is designed to accurately verify processes when procedures are performed following the instructions provided in this package insert and the *Panther/Panther Fusion System Operator's Manual*.

Interpretation of Results

The Panther Fusion System automatically determines the test results for samples and controls. Results for *Yersinia enterocolitica*, *Vibrio* species, *Escherichia coli* O157, and *Plesiomonas shigelloides* detection are reported separately. A test result may be negative, positive, or invalid.

The first valid result is the result that should be reported. Samples with invalid results should be retested. If the result is invalid upon retest, a new specimen should be collected.

Table 1 shows the possible results reported in a valid run with corresponding result interpretations.

Table 1: Result Interpretation

| Yersinia Result | Vibrio Result | O157 Result ^a | Plesio Result | IC Result | Interpretation |
|-----------------|---------------|--------------------------|---------------|-----------|---|
| Neg | Neg | Neg | Neg | Valid | <i>Yersinia enterocolitica</i> , <i>Vibrio</i> species, <i>E. coli</i> O157, and <i>Plesiomonas shigelloides</i> not detected. |
| POS | Neg | Neg | Neg | Valid | <i>Yersinia enterocolitica</i> detected. |
| Neg | POS | Neg | Neg | Valid | <i>Vibrio</i> species detected. |
| Neg | Neg | POS | Neg | Valid | <i>E. coli</i> O157 detected. |
| Neg | Neg | Neg | POS | Valid | <i>Plesiomonas shigelloides</i> detected. |
| POS | POS | Neg | Neg | Valid | <i>Yersinia enterocolitica</i> and <i>Vibrio</i> species detected. |
| POS | Neg | POS | Neg | Valid | <i>Yersinia enterocolitica</i> and <i>E. coli</i> O157 detected. |
| POS | Neg | Neg | POS | Valid | <i>Yersinia enterocolitica</i> and <i>Plesiomonas shigelloides</i> detected. |
| Neg | POS | POS | Neg | Valid | <i>Vibrio</i> species and <i>E. coli</i> O157 detected. |
| Neg | POS | Neg | POS | Valid | <i>Vibrio</i> species and <i>Plesiomonas shigelloides</i> detected. |
| Neg | Neg | POS | POS | Valid | <i>E. coli</i> O157 and <i>Plesiomonas shigelloides</i> detected. |
| POS | POS | POS | Neg | Valid | <i>Yersinia enterocolitica</i> , <i>Vibrio</i> species, and <i>E. coli</i> O157 detected. Infections with 3 bacteria are rare. Retest to confirm result. |
| POS | POS | Neg | POS | Valid | <i>Yersinia enterocolitica</i> , <i>Vibrio</i> species, and <i>Plesiomonas shigelloides</i> detected. Infections with 3 bacteria are rare. Retest to confirm result. |
| POS | Neg | POS | POS | Valid | <i>Yersinia enterocolitica</i> , <i>E. coli</i> O157, and <i>Plesiomonas shigelloides</i> detected. Infections with 3 bacteria are rare. Retest to confirm result. |
| Neg | POS | POS | POS | Valid | <i>Vibrio</i> species, <i>E. coli</i> O157, and <i>Plesiomonas shigelloides</i> detected. Infections with 3 bacteria are rare. Retest to confirm result. |
| POS | POS | POS | POS | Valid | <i>Yersinia enterocolitica</i> , <i>Vibrio</i> species, <i>E. coli</i> O157, and <i>Plesiomonas shigelloides</i> detected. Infections with 4 bacteria are rare. Retest to confirm result. |
| Invalid | Invalid | Invalid | Invalid | Invalid | Invalid. There was an error in the generation of the result; retest specimen. |

Neg = negative, POS = positive.

Note: POS result will be accompanied by cycle threshold (Ct) values. POS/HT represents a high titer result and will not have a Ct reported.

^a The Panther Fusion GI Bacterial Assay provides results for Shiga-toxin genes *stx1/stx2*. Note that strains of *E. coli* O157 that do not carry the Shiga-like toxin genes have been identified. However, the clinical significance of these non-STEC O157 strains has not been established.

Limitations

- A. Use of this assay is limited to personnel who are trained in this procedure. Failure to follow these instructions may result in erroneous results.
- B. Reliable results are dependent on adequate specimen collection, transport, storage, and processing.
- C. Avoid contamination by adhering to good laboratory practices and to the procedures specified in this package insert.
- D. Dehydrated Cary-Blair medium powders and Cary-Blair media in solid configuration with high agarose content were not evaluated and may not be compatible with the assay sample processing steps.
- E. The performance of this test has only been validated with human stool collected in liquid Cary-Blair transport medium, according to the media manufacturers' instructions.
- F. This product should not be used to test stool samples in fixative.
- G. The clinical performance characteristics for *Yersinia*, *Vibrio*, STEC O157 and *Plesiomonas shigelloides* were established primarily with contrived and archived samples due to low disease prevalence in the prospective collection.

Analytical Performance

Analytical Sensitivity

The analytical sensitivity (Limit of Detection or LoD) of the Panther Fusion GI Expanded Bacterial Assay was determined by testing dilutions of processed negative Cary-Blair Stool (CBS) matrix spiked with bacterial cultures of *Yersinia* (2 strains), *Vibrio* (3 strains), STEC O157 (2 strains), and *Plesiomonas* (2 strains). A minimum of 24 replicates were tested with each of the 3 reagent lots. The LoD for each analyte was determined by Probit analysis for each reagent lot and was confirmed with an additional 24 replicates using a single reagent lot in single analyte and multi-analyte configurations. Analytical sensitivity is defined as the lowest concentration at which ≥95% of all replicates tested positive, as summarized in Table 2.

Table 2: Analytical Sensitivity

| Strain | LoD Concentration (CFU/mL) ^a | |
|---|---|-----------------|
| | Aptima Multitest Tube | Preserved Stool |
| <i>Yersinia enterocolitica</i> , 33114 | 91 | 1820 |
| <i>Yersinia enterocolitica</i> , 1375, O:8 | 94 | 1880 |
| <i>Vibrio parahaemolyticus</i> , EB101 | 90 | 1800 |
| <i>Vibrio vulnificus</i> , B9629 | 10 | 200 |
| <i>Vibrio cholerae</i> , 8021 | 33 | 660 |
| STEC O157:H7, EDL 931 | 53 | 1060 |
| O157:NM, CDC 92-3073 | 357 | 7140 |
| <i>Plesiomonas shigelloides</i> , CDC 3085-55 | 65 | 1300 |
| <i>Plesiomonas shigelloides</i> , GNI 14 | 34 | 680 |

CFU = colony forming units.

^a Analyte concentrations in Aptima Multitest tube are ~20X dilute compared to preserved stool (~150 µL preserved stool in ~3 mL STM).

Inclusivity/Reactivity - Wet Testing

The inclusivity/reactivity of the Panther Fusion GI Expanded Bacterial Assay was determined by testing bacterial strains in processed negative CBS matrix. Each strain was tested in triplicate at 3X LoD with 1 reagent lot in single or multi-analyte configurations. For strains not detected at 3X LoD, additional testing at higher concentrations was performed until 100% positivity was observed. Table 3 shows the lowest concentration of each strain at which 100% positivity was observed.

Table 3: Inclusivity/Reactivity Summary for the GI Expanded Bacterial Assay Analytes

| Organism | ATCC# or Source | Strain/ Serovar/ Serotype/ Antigenic Properties | Test Concentration (3X LoD) (CFU/mL) | |
|--------------------------------|-------------------------|---|---|-----------------|
| | | | Aptima Multitest Tube | Preserved Stool |
| <i>Yersinia enterocolitica</i> | BEI NR-207 | CDC 497-70, O:8 | 282 | 5640 |
| | BEI NR-212 | NCTC 11175, O:3 | 282 | 5640 |
| | 23715 | Billups-1803-68, O:8 | 282 | 5640 |
| | 49397 ^c | 1375, O:8 | 282 | 5640 |
| | NCTC 10463 | P 77, O:5, 27 | 282 | 5640 |
| | CCUG 4588 | Type 2, O:9 | 282 | 5640 |
| | CCUG 8050 | N/A | 282 | 5640 |
| | CCUG 8232 | Type 5, O:1, 2, 3 O:2, 3 O:3/XI | 282 | 5640 |
| | CCUG 8234 | Type 4 | 282 | 5640 |
| | 55075 | O:9 | 282 | 5640 |
| 27729 | WA, Type 1, O:8 | 282 | 5640 | |
| <i>Vibrio parahaemolyticus</i> | BEI NR-21990 | 48057, O4: K12 | 270 | 5400 |
| | BEI NR-21992 | KXV 755, O4: K41 | 270 | 5400 |
| | BAA-242 | VP250, O1:KUT | 270 | 5400 |
| | 27969 | FC 1011 | 270 | 5400 |
| | BAA-241 | VP232, O4:K68 | 270 | 5400 |
| | 33845 | 117 [CDC KC830] | 270 | 5400 |
| | 43996 | NCTC 10884 [70/116655] | 270 | 5400 |
| | 33846 | 205 [9302] | 270 | 5400 |
| | 49529 | MDL 3875-7-83, O4:K12 | 270 | 5400 |
| | CCUG 34902 | N/A | 270 | 5400 |
| | CCUG 67711 | N/A | 270 | 5400 |
| | 33847 | 279 [11590] | 270 | 5400 |
| <i>Vibrio vulnificus</i> | 33817 | 329 [CDC B3547], Biotype 2 | 33 | 660 |
| | BAA-86 | CDC 9505-95 | 33 | 660 |
| | CCUG 38297 | N/A | 33 | 660 |
| | CCUG 47321 | N/A | 33 | 660 |
| | 29306 | CDC A1402 [P. Baumann 328] | 33 | 660 |
| | 43382 | VVL1 | 33 | 660 |
| | 29307 | CDC A8694 | 33 | 660 |
| | CCUG 38297 ^b | N/A | 55 | 1100 |

Table 3: Inclusivity/Reactivity Summary for the GI Expanded Bacterial Assay Analytes (continued)

| Organism | ATCC# or Source | Strain/ Serovar/ Serotype/ Antigenic Properties | Test Concentration (3X LoD) (CFU/mL) | |
|---------------------------------|----------------------------|--|---|-----------------|
| | | | Aptima Multitest Tube | Preserved Stool |
| <i>Vibrio cholerae</i> | BEI NR-147 | N16961, O:1 | 99 | 1980 |
| | BEI NR-148 | CVD 101, O:1 | 99 | 1980 |
| | BEI NR-149 | Nanking 32/123, O:2 | 99 | 1980 |
| | BEI NR-152 | Nanking 32/124 (NCTC 8042), O:7 | 99 | 1980 |
| | 14033 | NCTC 8457 [R. Hugh 1092], O1, Inaba | 99 | 1980 |
| | 9459 | AMC 20-A-10 [R. Hugh 583], Inaba | 99 | 1980 |
| | CCUG 2573 | NAG/NCV | 99 | 1980 |
| | CCUG 2569 | NAG/NCV | 99 | 1980 |
| | CCUG 4070 | Non O-1 | 99 | 1980 |
| | CCUG 21589 | 18 | 99 | 1980 |
| | CCUG 56875 | N/A | 99 | 1980 |
| | CCUG 53725 | O1/O139 | 99 | 1980 |
| | CCUG14542 | N/A | 99 | 1980 |
| | 9458 | AMC 20-A-41 [R. Hugh 582], Ogawa | 99 | 1980 |
| 25870 | 569B | 99 | 1980 | |
| STEC O157: H7 | 43890 | CDC C984 [CDC 3526-87], H7 | 159 | 3180 |
| | 43895 | CDC EDL 933, H7 | 159 | 3180 |
| | 43894 | CDC EDL 932, H7 | 159 | 3180 |
| | 700927 | EDL 933, H7:K- | 159 | 3180 |
| STEC O157: NM | 700375 | CDC 94-G7771, NM | 1197 | 23940 |
| | 700377 | CDC 92-3099, NM | 1197 | 23940 |
| | 700378 ^c | CDC 92-3073, NM | 1197 | 23940 |
| | AR Bank # 427 ^a | N/A | 1197 | 23940 |
| | AR Bank # 428 ^a | N/A | 1197 | 23940 |
| | AR Bank # 429 ^a | N/A | 1197 | 23940 |
| | AR Bank # 430 ^a | N/A | 1197 | 23940 |
| <i>Plesiomonas shigelloides</i> | 14030 | CDC 16408 [Ferguson and Henderson C27, RH 864], O:17 | 195 | 3900 |
| | 51903 ^c | GNI 14 | 195 | 3900 |
| | 51572 | CIP 69.35 [2886] | 195 | 3900 |
| | CCUG 7041A | O17: H2 | 195 | 3900 |
| | CCUG 9221 | O17 | 195 | 3900 |
| | CCUG 14309 | O17: H2 | 195 | 3900 |
| | CCUG 14597 | N/A | 195 | 3900 |

CFU = colony forming units.

^a These strains were evaluated using the higher LoD of the 2 serotypes which is the NM serotype.^b For this strain 100% positivity was observed at ~ 5X LoD. *In silico* analysis showed 100% homology to the amplification region.^c Strains used to establish LoD.

Inclusivity/Reactivity - *In Silico* Analysis

The inclusivity of the Panther Fusion GI Expanded Bacterial Assay was evaluated using *in silico* inclusivity analysis for each analyte. *In silico* analysis was performed using analyte sequences available in the NCBI database and in the whole genome shotgun sequence database. For each analyte, corresponding oligonucleotide sequences (primers and probes) were evaluated against the database sequences. Any sequences with insufficient lengths (not covering the entire amplicon region) were excluded from the analysis.

Based on *in silico* analysis of all sequences available up to March 26, 2024 in the databases, the Panther Fusion GI Expanded Bacterial Assay is predicted to detect 99.9% of 1054 *Yersinia Enterocolitica*, 99.5% of 1337 *Vibrio parahaemolyticus*, 99.1% of 1180 *Vibrio vulnificus*, 98.0% of 1189 *Vibrio cholerae*, 100% of 2004 STEC O157, and 91.5% of 47 *Plesiomonas shigelloides* sequences evaluated.

Analytical Specificity: Cross-Reactivity and Microbial Interference - Wet Testing

Analytical specificity (cross-reactivity) and microbial interference for the Panther Fusion GI Expanded Bacterial Assay were evaluated in the presence of non-targeted microorganisms that are either phylogenetically related to the assay analytes or potentially found in clinical specimens. Panels consisting of 109 bacteria, viruses, parasites, and yeast listed in Table 4 were tested in processed negative CBS matrix in the absence and in the presence of Panther Fusion GI Expanded Bacterial Assay analytes at 3X LoD. Except where noted, bacteria, yeast, and parasites were evaluated at 10⁶ CFU/mL or 10⁶ rRNA copies/mL or 10⁶ cells/mL; viruses were evaluated at 10⁵ TCID₅₀/mL. If cross-reactivity or interference was observed in the initial testing, then the organism was tested at lower concentrations until the expected result was observed. No cross-reactivity or microbial interference was observed with any of the organisms tested on the Panther Fusion GI Expanded Bacterial Assay at the indicated concentrations.

Table 4: Microorganisms Tested for Cross-Reactivity and Microbial Interference

| Microorganism | Test Concentration | Microorganism | Test Concentration |
|--|---------------------------------|----------------------------------|------------------------|
| <i>Arcobacter cryaerophilus</i> | 10 ⁶ CFU/mL | <i>Enterococcus faecalis</i> | 10 ⁶ CFU/mL |
| <i>Neisseria gonorrhoeae</i> | 10 ⁶ CFU/mL | <i>Enterobacter aerogenes</i> | 10 ⁶ CFU/mL |
| <i>Streptococcus pyogenes</i> | 10 ⁶ CFU/mL | <i>Enterobacter cloacae</i> | 10 ⁶ CFU/mL |
| <i>Trabulsiella guamensis</i> | 10 ⁶ CFU/mL | <i>Escherichia fergusonii</i> | 10 ⁶ CFU/mL |
| <i>Faecalibacterium prausnitzii</i> | 10 ⁶ rRNA copies /mL | <i>Escherichia hermannii</i> | 10 ⁶ CFU/mL |
| <i>Escherichia coli</i> (non-shigatoxigenic) | 10 ⁶ CFU/mL | <i>Escherichia vulneris</i> | 10 ⁶ CFU/mL |
| <i>Giardia lamblia</i> BG-A ^a | 10 ⁶ copies/mL | <i>Gardnerella vaginalis</i> | 10 ⁶ CFU/mL |
| <i>Cyclospora</i> ^a | 10 ⁶ copies/mL | <i>Helicobacter pylori</i> | 10 ⁶ CFU/mL |
| <i>Cryptosporidium</i> ^a | 10 ⁶ copies/mL | <i>Klebsiella oxytoca</i> | 10 ⁶ CFU/mL |
| Norovirus (Noro GII) ^a | 10 ⁵ copies/mL | <i>Klebsiella ozaenae</i> | 10 ⁶ CFU/mL |
| Astrovirus ^a | 10 ⁵ copies/mL | <i>Klebsiella pneumoniae</i> | 10 ⁶ CFU/mL |
| Sapovirus (GII) ^a | 10 ⁵ copies/mL | <i>Lactobacillus acidophilus</i> | 10 ⁶ CFU/mL |
| Enterovirus (Ent V) ^a | 10 ⁵ copies/mL | <i>Lactobacillus crispatus</i> | 10 ⁶ CFU/mL |

Table 4: Microorganisms Tested for Cross-Reactivity and Microbial Interference (continued)

| Microorganism | Test Concentration | Microorganism | Test Concentration |
|--------------------------------------|--|--------------------------------------|--|
| Rhinovirus ^a | 10 ⁵ copies/mL | <i>Lactococcus lactis</i> | 10 ⁶ CFU/mL |
| Coronavirus 229E | 10 ⁵ TCID ₅₀ /mL | <i>Listeria grayi</i> | 10 ⁶ CFU/mL |
| Coxsackievirus Type B4 | 10 ⁵ TCID ₅₀ /mL | <i>Listeria monocytogenes</i> | 10 ⁶ CFU/mL |
| Adenovirus Type 7A | 10 ⁵ TCID ₅₀ /mL | <i>Morganella morganii</i> | 10 ⁶ CFU/mL |
| Rotavirus ^a | 10 ⁵ copies/mL | <i>Peptostreptococcus anaerobius</i> | 10 ⁶ CFU/mL |
| <i>Anaerococcus tetradius</i> | 10 ⁶ CFU/mL | <i>Peptostreptococcus micros</i> | 10 ⁶ rRNA copies /mL |
| <i>Abiotrophia defectiva</i> | 10 ⁶ CFU/mL | <i>Photobacterium damsela</i> | 10 ⁶ CFU/mL |
| <i>Acinetobacter baumannii</i> | 10 ⁶ CFU/mL | <i>Prevotella bivia</i> | 10 ⁶ CFU/mL |
| <i>Acinetobacter Iwoffii</i> | 10 ⁶ CFU/mL | <i>Prevotella melaninogenica</i> | 10 ⁶ CFU/mL |
| <i>Aeromonas hydrophila</i> | 10 ⁶ CFU/mL | <i>Proteus mirabilis</i> | 10 ⁶ rRNA copies /mL |
| <i>Alcaligenes faecalis</i> | 10 ⁶ CFU/mL | <i>Proteus penneri</i> | 10 ⁶ CFU/mL |
| <i>Campylobacter upsaliensis</i> | 10 ⁶ CFU/mL | <i>Proteus vulgaris</i> | 10 ⁶ CFU/mL |
| <i>Anaerococcus vaginalis</i> | 10 ⁶ CFU/mL | <i>Providencia alcalifaciens</i> | 10 ⁶ CFU/mL |
| <i>Arcobacter butzleri</i> | 10 ⁶ CFU/mL | <i>Providencia rettgeri</i> | 10 ⁶ CFU/mL |
| <i>Bacillus cereus</i> | 10 ⁶ CFU/mL | <i>Providencia stuartii</i> | 10 ⁶ CFU/mL |
| <i>Bacteroides fragilis</i> | 10 ⁶ CFU/mL | <i>Pseudomonas aeruginosa</i> | 10 ⁶ CFU/mL |
| <i>Bacteroides thetaiotaomicron</i> | 10 ⁶ CFU/mL | <i>Pseudomonas fluorescens</i> | 10 ⁶ CFU/mL |
| <i>Bacteroides vulgatus</i> | 10 ⁶ CFU/mL | <i>Serratia liquefaciens</i> | 10 ⁶ CFU/mL |
| <i>Bifidobacterium adolescentis</i> | 10 ⁶ CFU/mL | <i>Serratia marcescens</i> | 10 ⁶ CFU/mL |
| <i>Bifidobacterium longum</i> | 10 ⁶ rRNA copies /mL | <i>Staphylococcus aureus</i> | 10 ⁶ CFU/mL |
| <i>Campylobacter fetus</i> | 10 ⁶ CFU/mL | <i>Staphylococcus epidermidis</i> | 10 ⁶ CFU/mL |
| <i>Campylobacter hyointestinalis</i> | 10 ⁶ CFU/mL | <i>Stenotrophomonas maltophilia</i> | 10 ⁶ CFU/mL |
| <i>Campylobacter rectus</i> | 10 ⁶ CFU/mL | <i>Streptococcus anginosus</i> | 10 ⁶ CFU/mL |
| <i>Campylobacter sputorum</i> | 10 ⁶ CFU/mL | <i>Streptococcus dysgalactiae</i> | 10 ⁶ CFU/mL |
| <i>Candida albicans</i> | 10 ⁶ CFU/mL | <i>Yersinia bercovieri</i> | 10 ⁶ CFU/mL |
| <i>Citrobacter freundii</i> | 10 ⁶ CFU/mL | <i>Yersinia pseudotuberculosis</i> | 10 ⁶ CFU/mL |
| <i>Citrobacter koseri</i> | 10 ⁶ CFU/mL | <i>Yersinia rohdei</i> | 10 ⁶ CFU/mL |
| <i>Clostridium difficile</i> | 10 ⁶ CFU/mL | <i>Campylobacter lari</i> | 10 ⁶ CFU/mL |
| <i>Clostridium perfringens</i> | 10 ⁶ CFU/mL | <i>Entamoeba histolytica</i> | 10 ⁴ cells/mL |
| <i>Clostridium ramosum</i> | 10 ⁶ CFU/mL | <i>Megasphaera elsdenii</i> | 10 ⁶ CFU/mL |
| <i>Clostridium sordellii</i> | 10 ⁶ CFU/mL | <i>Chlamydia trachomatis</i> | 10 ⁵ IFU/mL |
| <i>Clostridium tertium</i> | 10 ⁶ CFU/mL | <i>Leptotrichia buccalis</i> | 10 ⁶ CFU/mL |
| <i>Collinsella aerofaciens</i> | 10 ⁶ CFU/mL | <i>Cytomegalovirus</i> | 10 ⁵ TCID ₅₀ /mL |
| <i>Corynebacterium genitalium</i> | 10 ⁶ CFU/mL | <i>Salmonella enterica</i> | 10 ⁶ CFU/mL |
| <i>Cronobacter sakazakii</i> | 10 ⁶ CFU/mL | <i>Campylobacter jejuni</i> | 10 ⁶ CFU/mL |
| <i>Edwardsiella tarda</i> | 10 ⁶ CFU/mL | <i>Shigella sonnei</i> | 10 ⁶ CFU/mL |
| <i>Eggerthella lenta</i> | 10 ⁶ rRNA copies /mL | STEC - <i>stx1</i> | 10 ⁶ CFU/mL |

Table 4: Microorganisms Tested for Cross-Reactivity and Microbial Interference (continued)

| Microorganism | Test Concentration | Microorganism | Test Concentration |
|-----------------------------|------------------------|--|------------------------|
| STEC - <i>stx2</i> | 10 ⁶ CFU/mL | <i>Vibrio mimicus</i> | 10 ⁶ CFU/mL |
| <i>Vibrio fluvialis</i> | 10 ⁶ CFU/mL | <i>Yersinia frederiksenii</i> | 10 ⁶ CFU/mL |
| <i>Vibrio furnissii</i> | 10 ⁶ CFU/mL | <i>Yersinia kristensenii</i> | 10 ⁶ CFU/mL |
| <i>Vibrio metschnikovii</i> | 10 ⁶ CFU/mL | <i>Vibrio alginolyticus</i> ^b | 10 ⁴ CFU/mL |

CFU = colony forming units, IFU = inclusion forming units, rRNA copies = ribosomal ribonucleic acid copies, TCID₅₀ = Median Tissue Culture Infectious Dose.

^a *In vitro* transcripts were used to evaluate cross-reactivity and microbial interference as cultured virus or whole genome purified nucleic acid are not readily available.

^b Cross reactivity was observed at concentrations ≥10⁵ CFU/mL.

Coinfection/Competitive Interference

Competitive interference in the Panther Fusion GI Expanded Bacterial Assay was evaluated in triplicate using pairs of assay analytes at low/high concentrations in processed negative CBS matrix. The low concentration analyte was tested at 3X LoD against a high concentration analyte at 10⁶ CFU/mL. Additionally, analytes were also tested in the absence of a second analyte. If less than 100% positivity was observed for the low concentration analyte, the high concentration analyte was diluted until a concentration was reached where 100% positivity was achieved for the low concentration analyte. The highest concentration of competing analyte at which the low concentration analyte maintained a 100% positivity is shown in Table 5. When the analytes were tested at high concentration, all results for other analytes maintained expected positivity; no competitive interference was observed.

Table 5: Summary of Coinfection Results

| Analyte 1 | | Analyte 2 | | Yersinia % Pos | Vibrio % Pos | STEC O157 % Pos | Plesiomonas % Pos |
|-----------|---------------------------------|----------------------------|------------------------------------|-------------------|-----------------|--------------------|----------------------|
| Name | 3X LoD (CFU/mL) ^a | Name | High Conc (CFU/mL) ^a | | | | |
| Negative | NA | Negative | NA | 0% | 0% | 0% | 0% |
| Yersinia | 282 | None | 0 | 100% | 0% | 0% | 0% |
| | | <i>Vibrio</i> ^b | 10 ⁴ | 100% | 100% | 0% | 0% |
| | | STEC O157 | 10 ⁶ | 100% | 0% | 100% | 0% |
| | | <i>Plesiomonas</i> | 10 ⁶ | 100% | 0% | 0% | 100% |
| Vibrio | 270 | None | 0 | 0% | 100% | 0% | 0% |
| | | <i>Yersinia</i> | 10 ⁶ | 100% | 100% | 0% | 0% |
| | | STEC O157 | 10 ⁶ | 0% | 100% | 100% | 0% |
| | | <i>Plesiomonas</i> | 10 ⁶ | 0% | 100% | 0% | 100% |

Table 5: Summary of Coinfection Results (continued)

| | | | | | | | |
|--------------------|-------|----------------------------|-----------------|------|------|------|------|
| STEC O157 | 1;197 | None | 0 | 0% | 0% | 100% | 0% |
| | | <i>Yersinia</i> | 10 ⁶ | 100% | 0% | 100% | 0% |
| | | <i>Vibrio</i> ^b | 10 ⁴ | 0% | 100% | 100% | 0% |
| | | <i>Plesiomonas</i> | 10 ⁶ | 0% | 0% | 100% | 100% |
| <i>Plesiomonas</i> | 195 | None | 0 | 0% | 0% | 0% | 100% |
| | | <i>Yersinia</i> | 10 ⁶ | 100% | 0% | 0% | 100% |
| | | <i>Vibrio</i> | 10 ⁶ | 0% | 100% | 0% | 100% |
| | | STEC O157 | 10 ⁶ | 0% | 0% | 100% | 100% |
| None | 0 | <i>Yersinia</i> | 10 ⁶ | 100% | 0% | 0% | 0% |
| | | <i>Vibrio</i> | 10 ⁶ | 0% | 100% | 0% | 0% |
| | | STEC O157 | 10 ⁶ | 0% | 0% | 100% | 0% |
| | | <i>Plesiomonas</i> | 10 ⁶ | 0% | 0% | 0% | 100% |

CFU = colony forming units, Conc = concentration, Pos = positive.

^a Analyte concentration in Aptima Multitest tube.

^b Less than 100% positive results were observed for analyte 1 with *Vibrio* at $\geq 10^5$ CFU/mL.

Interference

Potential inhibitory effects of endogenous and exogenous substances that may be present in a specimen were evaluated in the Panther Fusion GI Expanded Bacterial Assay. Clinically relevant concentrations of potentially interfering substances were added to processed negative CBS matrix and tested in the absence and in the presence of GI Expanded Bacterial Assay analytes at 3X LoD. Tests were performed in triplicate. The substances and test concentrations are shown in Table 6.

No impact on the performance of the Panther Fusion GI Expanded Bacterial Assay was observed for any of the substances at the concentrations tested.

Table 6: Substances Tested for Interference

| Substance Type | Generic Name | Active Ingredient(s) | Test Concentration ^{a, b, c} |
|---------------------------------|---|--|---------------------------------------|
| Antibiotics | Amoxicillin | Amoxicillin | 0.7 µg/mL |
| | Ampicillin | Ampicillin | 0.9 µg/mL |
| | Doxycycline | Doxycycline | 0.2 µg/mL |
| | Metronidazole | Metronidazole | 1.5 µg/mL |
| | Neosporin® | Polymyxin B sulfate, bacitracin zinc, neomycin sulfate | 1.3% w/v |
| Antimicrobial and antifungal | BZK Antiseptic Towelettes | Benzalkonium chloride | 1.3% v/v |
| | Nystatin | Nystatin | 1.3% v/v |
| Laxatives and stool softeners | Dulcolax® suppository | Bisacodyl | 75 ng/mL |
| | Colace® | Docusate sodium | 3.0 µg/mL |
| | Fleet® mineral oil enema | Mineral oil | 1.3% v/v |
| | Ex-Lax® | Sennosides | 0.8 µg/mL |
| | Miralax® | Polyethylene glycol 3350 | 0.1 mg/mL |
| | Milk of Magnesia | Magnesium hydroxide, Aluminum hydroxide | 1.3% v/v |
| | Visicol® | Sodium phosphate | 53 ng/mL |
| Anti-diarrheal | Imodium® | Loperamide hydrochloride | 0.1 µg/mL |
| Anti-itch | Vagisil® | Benzocaine | 1.3% w/v |
| | Preparation H® | Hydrocortisone | 1.3% w/v |
| Anti-inflammatory | Phenylephrine hydrochloride (for hemorrhoids) | Phenylephrine hydrochloride | 0.4 ng/mL |
| | Mesalazine (Rx only, for Crohn's disease/ ulcerative colitis) | Salicylic acid | 0.4 µg/mL |
| | Aleve® | Naproxen sodium | 4.5 µg/mL |
| Antacid | Pepto-Bismol® | Bismuth subsalicylate | 1.3% v/v |
| | Tums® | Calcium carbonate | 55 µg/mL |
| Radiopaque contrast material | Barium sulfate | Barium sulfate | 0.1 mg/mL |
| Lubricants and skin protectants | K-Y® Personal Lubricant Jelly Glycerin | Glycerin | 1.3% w/v |
| | Vaseline® Original 100% Pure Petroleum Jelly White | Petrolatum | 1.3% w/v |
| | Desitin® | Zinc oxide | 1.3% w/v |

Table 6: Substances Tested for Interference (continued)

| Substance Type | Generic Name | Active Ingredient(s) | Test Concentration ^{a, b, c} |
|----------------|---|------------------------|---------------------------------------|
| Spermicide | Options Conceptrol® Vaginal Contraceptive Gel | Nonoxynol-9 | 1.3% w/v |
| | Cholesterol | Cholesterol | 50 µg/mL |
| | Fatty acids | Palmitic acid | 16 µg/mL |
| | Fatty acids | Stearic acid | 34 µg/mL |
| Endogenous | Triglycerides, total (Fecal fat, Intralipid) | Triglycerides | 1.3% v/v |
| | Human bile | Bilirubin, conjugated | 5.0 µg/mL |
| | Urine | Human urine | 1.3% v/v |
| | Human whole blood | Blood/hemoglobin | 1.3% v/v |
| | Mucin ^d | Purified mucin protein | 0.05% w/v |

^a Substance concentration in Aptima Multitest tube.

^b v/v: volume by volume.

^c w/v: weight by volume.

^d Interference was observed in higher concentrations of Mucin.

Stool specimens prepared in various preservative media were evaluated for potential impact on the Panther Fusion GI Expanded Bacterial Assay performance. The preservative media evaluated include 10 different types of Cary-Blair transport media from different vendors and preservative media containing fixatives shown in Table 7. All media were tested with GI Expanded Bacterial Assay analytes at 3X LoD. Comparable performance was seen with all Cary-Blair media. Comparable interference was observed when specimens were processed in media containing fixatives.

Table 7: Stool Preservative Media Tested for Interference

| Cary-Blair Media | |
|--|---|
| Culture & Sensitivity (C&S) Medium | Protocol Cary-Blair Medium |
| Cary-Blair Transport Medium w/ Indicator | Enteric Transport Media (ETM) |
| Para-Pak® C&S | Puritan® Cary-Blair Medium 2mL |
| Para-Pak® Enteric Plus | Puritan® Cary-Blair Medium 5mL |
| Cardinal Health™ C&S Stool Transport Vial | Copan® FecalSwab® Collection, Transport and Preservation System |
| Fixative Media (interference was observed) | |
| | Fisher® 10% Buffered Formalin |
| | Para-Pak® 10% Buffered Formalin |
| | Para-Pak® LV-PVA |

Carryover Contamination

Panther Fusion GI Bacterial Assay and GI Expanded Bacterial Assay belong to the same family of assays that both utilize Cary-Blair Stool as the sample type and follow identical assay processing steps. Carryover contamination was evaluated using Panther Fusion GI Bacterial Assay as a representative assay and demonstrated a 0% carryover rate.

Within Laboratory Precision/Repeatability

Panther Fusion GI Expanded Bacterial Assay within laboratory precision was evaluated with a 5-member panel consisting of assay analytes in processed negative CBS matrix. The 5-member panel included 1 negative, 2 single analyte (*Yersinia*), and 2 multi-analyte (with *Vibrio*, STEC O157, and *Plesiomonas*) panel members. The panels were tested by 3 operators on 2 runs per day, using 3 reagent lots on 3 Panther Fusion Systems over 9 days.

The panel members are described in Table 8, along with a summary of the agreement with the expected results, mean Ct, variability analysis between reagent lots, operators, instruments, days, between and within runs, and overall (total).

Table 8: Ct Variability Analysis Summary

| Panel | Description | Analyte | Agreed/N | Agreement % ^a | Mean Ct | Between Lots | | Between Instruments | | Between Operators | | Between Days | | Between Runs | | Within Run | | Total | |
|-------|--------------------|-----------------------------|----------|--------------------------|---------|--------------|--------|---------------------|--------|-------------------|--------|--------------|--------|--------------|--------|------------|--------|-------|--------|
| | | | | | | SD | CV (%) | SD | CV (%) | SD | CV (%) | SD | CV (%) | SD | CV (%) | SD | CV (%) | SD | CV (%) |
| 1 | Negative | Negative (Internal Control) | 162/162 | 100 | 28.0 | 0.11 | 0.39 | 0.32 | 1.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.42 | 0.14 | 0.51 | 0.39 | 1.39 |
| 2 | Low Pos (1.5X LoD) | <i>Yersinia</i> | 162/162 | 100 | 34.6 | 0.07 | 0.20 | 0.08 | 0.23 | 0.04 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 | 1.39 | 0.50 | 1.43 |
| 3 | Mod Pos (3X LoD) | <i>Yersinia</i> | 162/162 | 100 | 33.7 | 0.03 | 0.08 | 0.09 | 0.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.41 | 1.23 | 0.42 | 1.26 |
| 4 | Low Pos (1.5X LoD) | <i>Vibrio</i> | 162/162 | 100 | 33.7 | 0.12 | 0.35 | 0.07 | 0.21 | 0.01 | 0.04 | 0.00 | 0.00 | 0.17 | 0.52 | 0.23 | 0.69 | 0.32 | 0.95 |
| | | STEC O157 | 162/162 | 100 | 32.4 | 0.02 | 0.08 | 0.04 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.34 | 0.28 | 0.87 | 0.31 | 0.95 |
| | | <i>Plesiomonas</i> | 162/162 | 100 | 33.8 | 0.08 | 0.25 | 0.05 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | <0.01 | 0.03 | 0.25 | 0.73 | 0.26 | 0.78 |
| 5 | Mod Pos (3X LoD) | <i>Vibrio</i> | 162/162 | 100 | 32.7 | 0.07 | 0.21 | 0.12 | 0.37 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.57 | 0.20 | 0.06 | 0.30 | 0.93 |
| | | STEC O157 | 162/162 | 100 | 31.3 | 0.02 | 0.08 | 0.06 | 0.20 | 0.00 | 0.00 | 0.03 | 0.10 | 0.00 | 0.00 | 0.21 | 0.68 | 0.22 | 0.72 |
| | | <i>Plesiomonas</i> | 162/162 | 100 | 33.1 | 0.05 | 0.17 | <0.01 | 0.03 | 0.01 | 0.03 | 0.06 | 0.17 | 0.00 | 0.00 | 0.19 | 0.56 | 0.20 | 0.61 |

Ct = cycle threshold, CV = coefficient of variation, Mod = moderate, N = sample size, Pos = positive, SD = standard deviation.

^a Agreement to expected panel positivity result.

Reproducibility

Panther Fusion GI Expanded Bacterial Assay reproducibility was evaluated at 3 US sites using 1 negative panel member and 4 panel members positive for 1 or 3 targets. Testing was performed for 5 days by 6 operators (2 at each site) using 1 lot of assay reagents. Each run included 3 replicates of each panel member.

A negative panel member was created using a matrix comprised of stool specimens negative for all assay targets preserved in Cary-Blair media processed into STM. Positive panel members were created by spiking 1.5X LoD (low positive) or 3X LoD (moderate positive) concentrations of the target analytes into the negative matrix.

The agreement with expected results was 100% for all panel members for *Yersinia*, *Vibrio*, STEC O157, and *Plesiomonas* (Table 9).

Table 9: Agreement of Panther Fusion GI Expanded Bacterial Assay Results with Expected Results

| Description | Analyte | Agreement with Expected Results | |
|----------------------|---------------------------------|---------------------------------|----------------|
| | | N | % (95% CI) |
| Neg | Internal Control | 89/89 | 100 (95.9-100) |
| Low Pos ^a | <i>Yersinia</i> ^c | 90/90 | 100 (95.9-100) |
| | <i>Vibrio</i> ^c | 90/90 | 100 (95.9-100) |
| | STEC O157 ^c | 90/90 | 100 (95.9-100) |
| | <i>Plesiomonas</i> ^c | 90/90 | 100 (95.9-100) |
| Mod Pos ^b | <i>Yersinia</i> ^{c,d} | 90/90 | 100 (95.9-100) |
| | <i>Vibrio</i> ^c | 90/90 | 100 (95.9-100) |
| | STEC O157 ^c | 90/90 | 100 (95.9-100) |
| | <i>Plesiomonas</i> ^c | 90/90 | 100 (95.9-100) |

CI = score confidence interval, Mod = moderate, N = sample size, Neg = negative, Pos = positive.

^a Low Pos = All targets are 1.5X LoD.

^b Mod Pos = All targets are 3X LoD.

^c *Yersinia enterocolitica*, *Vibrio parahaemolyticus*, STEC O157, and *Plesiomonas shigelloides* strains were used to build the positive panels.

^d One (1) false positive *Vibrio* result was obtained for a moderate positive *Yersinia* panel member.

Signal variability was measured as %CV of the Ct values. The total signal variability was ≤1.61% (SD ≤0.55) for all panel components (Table 10). For the sources of variation except the 'within run' factor, %CV values were ≤1.03% for all panel components. The signal variability was ≤1.01% (SD ≤0.33) for the Panther Fusion GI Expanded Bacterial Assay positive controls (Table 11).

Table 10: Signal Variability of the Panther Fusion GI Expanded Bacterial Assay by Target and Concentration

| Description | Analyte | N | Between Site | | | Between Operator/Run ^c | | Between Day | | Within Run | | Total | |
|----------------------|--------------------|----|--------------|------|--------|-----------------------------------|--------|-------------|--------|------------|--------|-------|--------|
| | | | Mean Ct | SD | CV (%) | SD | CV (%) | SD | CV (%) | SD | CV (%) | SD | CV (%) |
| Low Pos ^a | <i>Yersinia</i> | 90 | 34.7 | 0.17 | 0.50 | 0.21 | 0.61 | 0.09 | 0.27 | 0.44 | 1.25 | 0.52 | 1.51 |
| | <i>Vibrio</i> | 90 | 33.7 | 0.16 | 0.49 | 0.08 | 0.25 | 0.00 | 0.00 | 0.26 | 0.77 | 0.32 | 0.95 |
| | STEC O157 | 90 | 32.4 | 0.17 | 0.53 | 0.13 | 0.41 | 0.00 | 0.00 | 0.30 | 0.92 | 0.37 | 1.14 |
| | <i>Plesiomonas</i> | 90 | 33.9 | 0.16 | 0.47 | 0.06 | 0.17 | 0.00 | 0.00 | 0.32 | 0.94 | 0.36 | 1.06 |
| Mod Pos ^b | <i>Yersinia</i> | 90 | 33.8 | 0.35 | 1.03 | 0.19 | 0.58 | 0.07 | 0.21 | 0.37 | 1.08 | 0.55 | 1.61 |
| | <i>Vibrio</i> | 90 | 32.7 | 0.20 | 0.60 | 0.09 | 0.26 | 0.11 | 0.35 | 0.22 | 0.68 | 0.33 | 1.01 |
| | STEC O157 | 90 | 31.4 | 0.24 | 0.75 | 0.08 | 0.27 | 0.07 | 0.21 | 0.26 | 0.81 | 0.36 | 1.16 |
| | <i>Plesiomonas</i> | 90 | 33.2 | 0.22 | 0.67 | 0.12 | 0.37 | 0.00 | 0.00 | 0.26 | 0.78 | 0.36 | 1.09 |

Ct = cycle threshold, CV = coefficient of variation, Mod = moderate, N = sample size, Pos = positive, SD = standard deviation.
 Note: The analysis was performed using the SAS MIXED procedure, which applies a lower boundary of 0 to all variance components in the model by default. If a variance component is 0, SD, and %CV are displayed as 0.00.

^a Low Pos = All targets are 1.5X LoD.

^b Mod Pos = All targets are 3X LoD.

^c Between Operator may be confounded with Between Run; therefore, Between Operator and Between Run estimates are combined in Between Operator/Run.

Table 11: Signal Variability of the Panther Fusion GI Expanded Bacterial Assay Positive Controls

| Control | Analyte | N | Between Site | | | Between Operator | | Between Day | | Within Day | | Total | |
|---------|--------------------|----|--------------|------|--------|------------------|--------|-------------|--------|------------|--------|-------|--------|
| | | | Mean Ct | SD | CV (%) | SD | CV (%) | SD | CV (%) | SD | CV (%) | SD | CV (%) |
| Pos | <i>Yersinia</i> | 30 | 32.7 | 0.22 | 0.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.75 | 0.33 | 1.01 |
| | <i>Vibrio</i> | 30 | 33.4 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 0.86 | 0.29 | 0.86 |
| | STEC O157 | 30 | 31.5 | 0.11 | 0.35 | 0.00 | 0.00 | 0.07 | 0.23 | 0.26 | 0.83 | 0.29 | 0.93 |
| | <i>Plesiomonas</i> | 30 | 32.9 | 0.05 | 0.16 | 0.08 | 0.23 | 0.12 | 0.37 | 0.24 | 0.74 | 0.29 | 0.87 |

Ct = cycle threshold, CV = coefficient of variation, N = sample size, Pos = positive, SD = standard deviation.

Note: The analysis was performed using the SAS MIXED procedure, which applies a lower boundary of 0 to all variance components in the model by default. If a variance component is 0, SD and %CV are displayed as 0.00.

Clinical Performance

A multicenter study was conducted using remnant stool specimens in Cary-Blair preservative medium collected as part of routine patient care at 10 US clinics from pediatric or adult patients suspected of acute gastroenteritis. All specimens were tested with the Panther Fusion GI Expanded Bacterial Assay and with comparator assays: a PCR plus bidirectional sequencing (run in duplicate) for STEC O157 and an FDA-cleared Nucleic Acid Amplification Test (NAAT) for all other targets. An alternate FDA-cleared NAAT was used for discordant resolution testing, if applicable. Positive (PPA) and negative (NPA) percent agreement, with corresponding 2-sided 95% Score CIs, were calculated relative to comparator results, by target and by specimen category.

A total of 1548 prospective specimens and 251 retrospective specimens were enrolled in the study; 94 specimens were excluded from the performance analyses (for example, duplicate individuals, invalid Panther Fusion GI Expanded Bacterial or comparator results for all targets). An additional 189 contrived specimens were assessed to supplement the prospective and retrospective data for all targets. Of the 1919 specimens tested in valid Panther Fusion GI Expanded Bacterial Assay runs, 36 (1.9%) had initial invalid results. Upon retest, 25 of the 36 specimens yielded valid results, for a total of 11 (0.6%) specimens with final invalid results. The final data set consisted of 1894 evaluable specimens (1523 prospective specimens, 182 retrospective specimens, and 189 contrived specimens); not all were evaluable for all analytes. Demographic information for the 1705 evaluable prospective and retrospective specimens is provided in Table 12.

Table 12: Summary of Subject Demographics

| | | Total N (%) | Prospective N (%) | Retrospective N (%) |
|-----------------|---------------------|-------------|-------------------|---------------------|
| Total Specimens | | 1705 | 1523 | 182 |
| Sex | Female | 888 (52.1) | 793 (52.1) | 95 (52.2) |
| | Male | 817 (47.9) | 730 (47.9) | 87 (47.8) |
| Age Group | 0 to 28 days | 7 (0.4) | 7 (0.5) | 0 (0) |
| | 29 days to <2 years | 74 (4.3) | 67 (4.4) | 7 (3.8) |
| | 2 to 5 years | 55 (3.2) | 50 (3.3) | 5 (2.7) |
| | 6 to 11 years | 68 (4.0) | 66 (4.3) | 2 (1.1) |
| | 12 to 17 years | 73 (4.3) | 71 (4.7) | 2 (1.1) |
| | 18 to 21 years | 47 (2.8) | 44 (2.9) | 3 (1.6) |
| | 22 to 64 years | 825 (48.4) | 724 (47.5) | 101 (55.5) |
| | ≥65 years | 556 (32.6) | 494 (32.4) | 62 (34.1) |

N = population size.

Performance characteristics for detection of *Yersinia*, *Vibrio*, STEC O157, and *Plesiomonas* are shown in Table 13 through Table 16.

Table 13: Clinical Performance - *Yersinia* spp.

| Specimen Origin | N | TP | FP | TN | FN | Prevalence ^a (%) | PPA % (95% CI) ^b | NPA % (95% CI) ^b |
|------------------------|------|----|----------------|------|----------------|-----------------------------|-----------------------------|-----------------------------|
| Prospective (Fresh) | 1507 | 10 | 9 ^c | 1487 | 1 ^d | 0.7 | 90.9 (62.3, 98.4) | 99.4 (98.9, 99.7) |
| Retrospective (Frozen) | 182 | 15 | 3 ^e | 164 | 0 | N/A ^f | 100 (79.6, 100) | 98.2 (94.9, 99.4) |
| Contrived (Frozen) | 189 | 63 | 0 | 126 | 0 | N/A ^f | 100 (94.3, 100) | 100 (97.0, 100) |

CI = confidence interval, FN = false negative, FP = false positive, N = sample size, NPA = negative percent agreement, PPA = positive percent agreement, TN = true negative, TP = true positive.

^a Study prevalence reported based on comparator testing.

^b Score CI.

^c 6 of 9 discordant false positive prospective specimens were positive for *Yersinia* by the alternate NAAT.

^d The discordant false negative prospective specimen was negative for *Yersinia* by the alternate NAAT.

^e The 3 discordant false positive retrospective specimens were positive for *Yersinia* by the alternate NAAT.

^f Calculation of prevalence is not applicable.

Table 14: Clinical Performance - *Vibrio* spp.

| Specimen Origin | N | TP | FP | TN | FN | Prevalence ^a (%) | PPA % (95% CI) ^b | NPA % (95% CI) ^b |
|------------------------|------|----|----------------|------|----------------|-----------------------------|-----------------------------|-----------------------------|
| Prospective (Fresh) | 1507 | 1 | 0 | 1505 | 1 ^c | 0.1 | 50.0 (9.5, 90.5) | 100 (99.7, 100) |
| Retrospective (Frozen) | 182 | 9 | 6 ^d | 167 | 0 | N/A ^f | 100 (70.1, 100) | 96.5 (92.6, 98.4) |
| Contrived (Frozen) | 189 | 63 | 1 ^e | 125 | 0 | N/A ^f | 100 (94.3, 100) | 99.2 (95.6, 99.9) |

CI = confidence interval, FN = false negative, FP = false positive, N = sample size, NPA = negative percent agreement, PPA = positive percent agreement, TN = true negative, TP = true positive.

^a Study prevalence reported based on comparator testing.

^b Score CI.

^c The discordant false negative prospective specimen was positive for *Vibrio* by the alternate NAAT.

^d All 6 discordant false positive retrospective specimens were positive for *Vibrio* by the alternate NAAT.

^e The discordant false positive contrived specimen was negative for *Vibrio* by the alternate NAAT.

^f Calculation of prevalence is not applicable.

Table 15: Clinical Performance - STEC O157

| Specimen Origin | N | TP | FP | TN | FN | Prevalence ^a (%) | PPA % (95% CI) ^b | NPA % (95% CI) ^b |
|------------------------|------|----|----------------|------|----------------|-----------------------------|-----------------------------|-----------------------------|
| Prospective (Fresh) | 1522 | 1 | 2 ^c | 1519 | 0 | 0.1 | 100 (20.7, 100) | 99.9 (99.5, 100) |
| Retrospective (Frozen) | 182 | 3 | 1 ^d | 178 | 0 | N/A ^g | 100 (43.9, 100) | 99.4 (96.9, 99.9) |
| Contrived (Frozen) | 189 | 62 | 1 ^e | 125 | 1 ^f | N/A ^g | 98.4 (91.5, 99.7) | 99.2 (95.6, 99.9) |

CI = confidence interval, FN = false negative, FP = false positive, N = sample size, NPA = negative percent agreement, PPA = positive percent agreement, TN = true negative, TP = true positive.

^a Study prevalence reported based on comparator testing.

^b Score CI.

^c 1 of 2 discordant false positive prospective specimens was negative for STEC O157 by the alternate NAAT. The other discordant was positive for O157 but negative for *stx1/stx2* by the alternate NAAT.

^d The discordant false positive retrospective specimen was positive for STEC O157 by the alternate NAAT.

^e The discordant false positive contrived specimen was negative for STEC O157 by the alternate NAAT.

^f The discordant false negative contrived specimen was not retested by the alternate NAAT.

^g Calculation of prevalence is not applicable.

Table 16: Clinical Performance - *Plesiomonas*

| Specimen Origin | N | TP | FP | TN | FN | Prevalence ^a (%) | PPA % (95% CI) ^b | NPA % (95% CI) ^b |
|------------------------|------|----|----------------|------|----------------|-----------------------------|-----------------------------|-----------------------------|
| Prospective (Fresh) | 1507 | 1 | 1 ^c | 1505 | 0 | 0.1 | 100 (20.7, 100) | 99.9 (99.6, 100) |
| Retrospective (Frozen) | 182 | 8 | 1 ^d | 173 | 0 | N/A ^f | 100 (67.6, 100) | 99.4 (96.8, 99.9) |
| Contrived (Frozen) | 189 | 62 | 0 | 126 | 1 ^e | N/A ^f | 98.4 (91.5, 99.7) | 100 (97.0, 100) |

CI = confidence interval, FN = false negative, FP = false positive, N = sample size, NPA = negative percent agreement, PPA = positive percent agreement, TN = true negative, TP = true positive.

^a Study prevalence reported based on comparator testing.

^b Score CI.

^c The discordant false positive prospective specimen was positive for *Plesiomonas* by the alternate NAAT.

^d The discordant false positive retrospective specimen was positive for *Plesiomonas* by the alternate NAAT.

^e The discordant false negative contrived specimen was not retested by the alternate NAAT.

^f Calculation of prevalence is not applicable.

No coinfections were detected by the Panther Fusion GI Expanded Bacterial Assay or by the comparator methods in prospective and retrospective specimens.

Bibliography

1. WHO's first ever global estimates of foodborne diseases find children under 5 account for almost one third of deaths. Published December 3, 2015. Accessed May 27, 2025. <https://www.who.int/news/item/03-12-2015-who-s-first-ever-global-estimates-of-foodborne-diseases-find-children-under-5-account-for-almost-one-third-of-deaths>
2. Centers for Disease Control and Prevention. Published date unknown. Burden of foodborne illness: Overview. U.S. Department of Health & Human Services. Retrieved May 27, 2025, from https://archive.cdc.gov/www_cdc_gov/foodborneburden/estimates-overview.html
3. Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults. *Am J Gastroenterol*. 2016;111(5):602–622. doi:10.1038/ajg.2016.141
4. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones JL, Griffin PM. Foodborne illness acquired in the United States—major pathogens. *Emerg Infect Dis*. 2011;17(1):7–15. doi:10.3201/eid1701.P11101
5. Ong KL, Gould LH, Chen DL, Jones TF, Scheftel J, Webb TH, Mody RK, Mahon BE. Changing epidemiology of *Yersinia enterocolitica* infections: markedly decreased rates in young black children, Foodborne Diseases Active Surveillance Network (FoodNet), 1996-2009. *Clin Infect Dis*. 2012 Jun;54 Suppl 5(0 5):S385-90. doi: 10.1093/cid/cis053.
6. Centers for Disease Control and Prevention. About Vibrio Infection. CDC. Updated May 14, 2024. Accessed June 2, 2025. <https://www.cdc.gov/vibrio/about/index.html>
7. Armed Forces Health Surveillance Division. *Escherichia coli*, Shiga Toxin-Producing (STEC) Reference Sheet. U.S. Department of Defense; 2022. Accessed May 30, 2025. <https://ph.health.mil/cdt/cphe-cdt-e-coli-shiga-toxin-producing-ref.pdf>
8. Morris JG Jr, Horneman A. *Plesiomonas shigelloides* infections. *UpToDate*. Calderwood SB, Baron EL, eds. Updated December 13, 2023. Accessed May 30, 2025. <https://www.uptodate.com/contents/plesiomonas-shigelloides-infections/print>
9. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections, 3rd ed. CLSI guideline M29. Clinical and Laboratory Standards Institute; 2014. Accessed May 30, 2025. <https://clsi.org/standards/products/microbiology/documents/m29/>

Contact Information



Hologic, Inc.
10210 Genetic Center Drive
San Diego, CA 92121 USA

For country-specific Technical Support and Customer Service, email address and telephone number, visit www.hologic.com/support.

Hologic, Aptima, Panther, Panther Fusion, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

All other trademarks that may appear in this package insert are the property of their respective owners.

This product may be covered by one or more U.S. patents identified at www.hologic.com/patents.

©2026 Hologic, Inc. All rights reserved.

AW-34806-001 Rev. 002
2026-04